Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
ESC Heart Fail. 2021 Jun;8(3):2172-2182. doi: 10.1002/ehf2.13309. Epub 2021 Mar 28.
Recent reports demonstrated that patients with heart failure (HF) might have an increased risk to develop malignancies. This is also seen in patients with chronic kidney disease (CKD). Immunosuppression in heart transplantation (HT) recipients additionally increases the risk of malignancies. The aim of this study was to determine the relation between HF duration and CKD pre-HT and the risk of malignancy development post-HT.
We included all adult HT recipients transplanted between January 2000 and November 2017 in our centre. Patients were excluded if they died or were retransplanted within 3 months post-HT. Clinical characteristics were retrospectively collected. Sixty out of 250 patients (24%) developed a malignancy after a median of 66 months [interquartile range 33-108] post-HT. In multivariable Cox regression analysis, HF duration was not a risk factor for all malignancies or solid organ malignancies post-HT [hazard ratio (HR) 1.033 (0.974-1.096), P = 0.281 and HR 1.036 (0.958-1.120), P = 0.376, respectively]. Age [HR 1.051 (1.016-1.086), P = 0.004] and CKD pre-HT [HR 2.173 (1.236-3.822), P = 0.007] were independent risk factors for all malignancies. CKD pre-HT [HR 2.542 (1.142-5.661), P = 0.022] increased the risk for solid organ malignancies. Exclusion of patients with durable mechanical circulatory support in the analysis did not alter the significance of these risk factors.
Duration of HF pre-HT was not associated with malignancy risk post-HT. CKD was an independent risk factor for malignancies post-HT. More studies are needed to investigate this association.
最近的报告表明,心力衰竭(HF)患者发生恶性肿瘤的风险可能会增加。慢性肾脏病(CKD)患者也存在这种情况。心脏移植(HT)受者的免疫抑制会进一步增加恶性肿瘤的风险。本研究旨在确定 HT 前 HF 持续时间和 CKD 与 HT 后恶性肿瘤发展风险之间的关系。
我们纳入了本中心 2000 年 1 月至 2017 年 11 月期间所有接受 HT 的成年患者。如果患者在 HT 后 3 个月内死亡或再次移植,则将其排除在外。回顾性收集临床特征。在 HT 后中位 66 个月[33-108]时,60 例患者(24%)发生恶性肿瘤。多变量 Cox 回归分析显示,HF 持续时间不是 HT 后所有恶性肿瘤或实体器官恶性肿瘤的危险因素[风险比(HR)1.033(0.974-1.096),P=0.281 和 HR 1.036(0.958-1.120),P=0.376]。年龄[HR 1.051(1.016-1.086),P=0.004]和 HT 前 CKD[HR 2.173(1.236-3.822),P=0.007]是所有恶性肿瘤的独立危险因素。HT 前 CKD[HR 2.542(1.142-5.661),P=0.022]增加了实体器官恶性肿瘤的风险。在分析中排除了具有持久机械循环支持的患者并没有改变这些危险因素的意义。
HT 前 HF 持续时间与 HT 后恶性肿瘤风险无关。CKD 是 HT 后恶性肿瘤的独立危险因素。需要进一步研究以探讨这种关联。